Cargando…
Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End‐Stage Kidney Disease
BACKGROUND: Heart failure with reduced ejection fraction (HFrEF) is a chronic disease with substantial mortality. Management of HFrEF has seen significant breakthrough after the launch of neprilysin inhibitor. The PARADIGM‐HF (Prospective Comparison of ARNI with ACEI to Determine Impacton Global Mor...
Autores principales: | Niu, Chih‐Yuan, Yang, Shang‐Feng, Ou, Shuo‐Ming, Wu, Cheng‐Hsueh, Huang, Po‐Hsun, Hung, Chung‐Lieh, Lin, Chih‐Ching, Li, Szu‐Yuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683670/ https://www.ncbi.nlm.nih.gov/pubmed/36062622 http://dx.doi.org/10.1161/JAHA.122.026407 |
Ejemplares similares
-
Sacubitril/valsartan in heart failure and end‐stage renal insufficiency
por: Heyse, Alex, et al.
Publicado: (2019) -
Renal protective effect of sacubitril/valsartan in patients with heart failure
por: Hsieh, Hui-Ling, et al.
Publicado: (2021) -
Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end‐stage of renal disease
por: Lee, Seonhwa, et al.
Publicado: (2020) -
Sacubitril–valsartan in heart failure and multimorbidity patients
por: Rodil Fraile, Raquel, et al.
Publicado: (2018) -
Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021)